Manwani, R.(2018). Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy. Blood, 132(Supplement 1), 3262-3262. doi:10.1182/blood-2018-99-116688

Manwani, Richa. "Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront With Bortezomib-Based Therapy". Blood, 132.Supplement 1 ( 2018 ): 3262-3262.